Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM)

被引：41

作者：

Puzanov, Igor

Callahan, Margaret K.

Linette, Gerald P.

Patel, Sapna Pradyuman

Luke, Jason J.

Sosman, Jeffrey Alan

Wolchok, Jedd D.

Hamid, Omid

Minor, David R.

Orford, Keith W.

Hug, Bruce A.

Ma, Bo

Matthys, Gemma M.

Hoos, Axel

机构：

[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[3] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Angeles Clin & Res Inst, Los Angeles, CA USA

[7] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA

[8] GlaxoSmithKline, Res & Dev, Collegeville, PA USA

[9] GlaxoSmithKline, Res & Dev, Res Triangle Pk, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.2511

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2511

引用

页数：1

共 50 条

[1] Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
Igor Puzanov
Journal of Translational Medicine, 13 (Suppl 1)
[2] Trametinib plus dabrafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations
Abraham, Jame
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (07): : 234 - 235
[3] Evaluating the Safety and Tolerability of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients with Metastatic BRAF V600E/K Mutation-positive Cutaneous Melanoma
Wang, T. W.
Smith, J. L.
Carlino, M.
Burmeister, B.
Pinkham, M. B.
Fogarty, G. B.
Christie, D.
Estall, V.
Shackleton, M.
Wolfe, R.
Phuong, T. L. T.
Paton, E. J.
Steel, V.
Williams, N. C.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S133 - S134
[4] Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
Planchard, David
Groen, Harry J. M.
Kim, Tae Min
Rigas, James R.
Souquet, Pierre Jean
Baik, Christina S.
Barlesi, Fabrice
Mazieres, Julien
Quoix, Elisabeth A.
Curtis, C. Martin
Mookerjee, Bijoyesh
Bartlett-Pandite, Arundathy N.
Tucker, Christine
D'Amelio, Anthony
Johnson, Bruce E.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[5] Early tumor immune microenvironment (TME) modulation by the BRAF inhibitor (BRAFi) dabrafenib (D) and/or the MEK inhibitor (MEKi) trametinib (T) in patients (pts) with BRAF V600E/K-mutant melanoma in the COMBAT trial
Robert, Caroline
Shen, Shensi
Allard, Delphine
Fernandez, Ana Arance
Dutriaux, Caroline
de Jong, Egbert
Squires, Matthew
Grob, Jean-Jacques
CANCER RESEARCH, 2018, 78 (13)
[6] Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM)
Schuchter, Lynn Mara
Kudchadkar, Ragini Reiney
Gonzalez, Rene
Lawrence, Donald P.
Sosman, Jeffrey Alan
Infante, Jeffrey R.
Daud, Adil
Kefford, Richard
Cebon, Jonathan S.
Sharfman, William Howard
Amaravadi, Ravi K.
Boasberg, Peter D.
Lewis, Karl D.
Flaherty, Keith
Ouellet, Danielle
Little, Shonda M.
Clark, Jennifer
Gibney, Geoffrey Thomas
Patel, Kiran
Hamid, Omid
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[7] BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM)
Sosman, Jeffrey Alan
Daud, Adil
Weber, Jeffrey S.
Kim, Kevin
Kefford, Richard
Flaherty, Keith
Infante, Jeffrey R.
Hamid, Omid
Cebon, Jonathan S.
Schuchter, Lynn Mara
McWilliams, Robert R.
Sznol, Mario
Sharfman, William Howard
Algazi, Alain Patrick
Lewis, Karl D.
Little, Shonda M.
Sun, Peng
Long, Georgina
Patel, Kiran
Gonzalez, Rene
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[8] BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
Saijo, Ken
Imai, Hiroo
Katayama, Hiromichi
Fujishima, Fumiyoshi
Nakamura, Kenichi
Kasahara, Yuki
Ouchi, Kota
Komine, Keigo
Shirota, Hidekazu
Takahashi, Masanobu
Ishioka, Chikashi
CASE REPORTS IN ONCOLOGY, 2022, 15 (02): : 762 - 769
[9] Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
Wang, Wei
Smith, Jessica Louise
Carlino, Matteo Salvatore
Burmeister, Bryan
Pinkham, Mark Blayne
Fogarty, Gerald Blaise
Christie, David Robert Harry
Estall, Vanessa
Shackleton, Mark
Clements, Arthur
Wolfe, Rory
Le Thi Phuong Thao
Paton, Elizabeth Jane
Steel, Victoria
Williams, Narelle Catherine
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2021, 30 : 95 - 99
[10] Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
Atreya, Chloe Evelyn
Van Cutsem, Eric
Bendell, Johanna C.
Andre, Thierry
Schellens, Jan H. M.
Gordon, Michael S.
McRee, Autumn Jackson
O'Dwyer, Peter J.
Muro, Kei
Tabernero, Josep
van Geel, Robin
Sidhu, Roger
Greger, James G.
Rangwala, Fatima A.
Motwani, Monica
Wu, Yuehui
Orford, Keith W.
Corcoran, Ryan Bruce
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →